{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T17:52:33Z","timestamp":1793555553200,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Finnish Funding Agency for Technology and Innovation","award":["40343\/05"],"award-info":[{"award-number":["40343\/05"]}]},{"name":"Finnish Funding Agency for Technology and Innovation","award":["599\/05"],"award-info":[{"award-number":["599\/05"]}]},{"name":"Hormos Medical Ltd, Finland (subsidiary of QuatRx Pharmaceutical, USA)"},{"name":"Biotop Oy, Finland"},{"name":"Genolyze Oy, Finland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ygyno.2012.03.011","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T20:31:49Z","timestamp":1331929909000},"page":"667-672","source":"Crossref","is-referenced-by-count":41,"title":["Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women"],"prefix":"10.1016","volume":"125","clinical-trial-number":[{"clinical-trial-number":"nct01301885","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"M.","family":"Hallamaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Suvitie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Huhtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Matom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Poutanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perheentupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.03.011_bb0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0002-9378(86)90077-3","article-title":"The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer","volume":"155","author":"Niloff","year":"1986","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ajcp\/79.1.98","article-title":"Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types","volume":"79","author":"Kabawat","year":"1983","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/172460089801300411","article-title":"CA 125 in benign gynecological conditions","volume":"13","author":"Meden","year":"1998","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0025","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0002-9378(88)90803-4","article-title":"CA 125 in serum, peritoneal fluid, active lesions, and endometrium of patients with endometriosis","volume":"158","author":"Fedele","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0030","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0015-0282(16)49812-2","article-title":"The use of CA-125 in the diagnosis and management of endometriosis","volume":"46","author":"Pittaway","year":"1986","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(88)90351-0","article-title":"Multimodal approach to screening for ovarian cancer","volume":"1","author":"Jacobs","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0040","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1525-1438.2005.00441.x","article-title":"New tumor markers: CA125 and beyond","volume":"15 Suppl 3","author":"Bast","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0045","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/1097-0142(20000801)89:3<582::AID-CNCR13>3.0.CO;2-#","article-title":"Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography","volume":"89","author":"Sato","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0050","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1006\/gyno.2000.5816","article-title":"The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer","volume":"77","author":"van Nagell","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0055","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2008.19.2484","article-title":"Development of a multimarker assay for early detection of ovarian cancer","volume":"28","author":"Yurkovetsky","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2012.03.011_bb0060","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0065","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.ygyno.2012.03.011_bb0070","doi-asserted-by":"crossref","first-page":"228.e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0075","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0080","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0085","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","article-title":"Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence","volume":"110","author":"Havrilesky","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0095","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","article-title":"The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass","volume":"23","author":"Montagnana","year":"2009","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0105","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1055-9965.EPI-08-0150","article-title":"Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer","volume":"17","author":"Lowe","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0110","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00404-006-0242-z","article-title":"Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle","volume":"275","author":"Kafali","year":"2007","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1155\/1999\/960934","article-title":"Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19\u20139, CA 125 and CA 15\u20133 in healthy women","volume":"15","author":"Erba\u011fci","year":"1999","journal-title":"Dis Markers"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0125","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/humrep\/14.2.566","article-title":"Fluctuations in CA 125 and CA 15\u20133 serum concentrations during spontaneous ovulatory cycles","volume":"14","author":"Bon","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0130","first-page":"75","article-title":"Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis","volume":"49","author":"Matalliotakis","year":"2004","journal-title":"Int J Fertil Womens Med"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0135","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.fertnstert.2006.02.082","article-title":"The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis","volume":"86","author":"de S\u00e1 Rosa e Silva","year":"2006","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.ygyno.2012.03.011_bb0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13277-010-0049-1","article-title":"Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IGC.0b013e318234f852","article-title":"The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis","volume":"22","author":"Kadija","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.12.029","article-title":"Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders","volume":"206","author":"Moore","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0155","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0015-0282(97)81391-X","article-title":"Revised American Society for Reproductive Medicine classification of endometriosis","volume":"67","year":"1997","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0160","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/17530059.2011.559459","article-title":"fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma","volume":"5","author":"Hellstrom","year":"2011","journal-title":"Expert Opin Med Diagn"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0165","doi-asserted-by":"crossref","first-page":"200s","DOI":"10.1200\/JCO.2003.01.068","article-title":"Status of tumor markers in ovarian cancer screening","volume":"21","author":"Bast","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0170","doi-asserted-by":"crossref","first-page":"475983","DOI":"10.1155\/2011\/475983","article-title":"Potential markers for detection and monitoring of ovarian cancer","volume":"2011","author":"Rein","year":"2011","journal-title":"J Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.03.011_bb0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1447-0756.1992.tb00329.x","article-title":"Effect of menstruation on serum CA125 levels","volume":"18","author":"Kan","year":"1992","journal-title":"Asia Oceania J Obstet Gynaecol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9378(87)90207-9","article-title":"Serum CA-125 antigen levels increase during menses","volume":"156","author":"Pittaway","year":"1987","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0190","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/humrep\/deh890","article-title":"Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas","volume":"20","author":"Kitawaki","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00000441-198607000-00005","article-title":"Evaluation of serum CA125 values in healthy individuals and pregnant women","volume":"292","author":"Haga","year":"1986","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0200","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/gyno.1994.1093","article-title":"What is a normal CA125 level?","volume":"53","author":"Alagoz","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1006\/gyno.1995.1245","article-title":"The effect of renal function on serum levels of CA 125","volume":"58","author":"Menzin","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.03.011_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejogrb.2004.02.039","article-title":"Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report","volume":"116","author":"Kafali","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812001825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812001825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T11:06:39Z","timestamp":1561460799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812001825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0090825812001825"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.03.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}